Dicot Pharma AB (STO:DICOT)

Market Cap	709.69M -50.6%
Revenue (ttm)	n/a
Net Income	-72.14M
EPS	-0.04
Shares Out	3.47B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,210,898
Open	0.2012
Previous Close	0.2046
Day's Range	0.1966 - 0.2078
52-Week Range	0.1750 - 1.1800
Beta	0.86
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Dicot Pharma AB

Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2015
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DICOT

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 13, 2026

Data Sources Report a data error